Stocks · News reference
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
TransMedics stock fell 8% after Q2 earnings showed 21% sales growth but adjusted net income dropped more than 50% due to reinvestment in new kidney organ care systems and manufacturing. Despite the decline, the analyst remains bullish on the stock, citing upcoming clinical trials for heart and lung systems, a new kidney OCS in development, and European expansion opportunities.
Read original at the-motley-foolPiper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.
Read original at benzingaU.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 revenue but a loss. Other stocks also decline.
Read original at benzinga